Pneumococcal Polysaccharide Vaccine Market - Forecast(2024 - 2030)

Pneumococcal Polysaccharide Vaccine Market Overview

The Pneumococcal Polysaccharide Vaccine Market size is estimated to reach $11.2 billion by 2027. Furthermore, it is poised to grow at a CAGR of 5.2% over the forecast period of 2022-2027. Streptococcus pneumoniae bacterial is the primary bacteria responsible for causing pneumonia in adults and youths. To prevent any seriousness in adults or youths, the vaccines which are registered in India are Prevnar 13 and Pneumovax 23. Moreover, the Streptococcus pneumoniae bacteria owing to its virulence factors are able to minimize phagocytosis. Additionally, there are a lot of nutrients that use phagocytosis to obtain nutrients. The bacteria as listed above has the capacity to infect the lungs and the blood lining of the brain and spinal cord. With the advent of vaccines, children and adults’ immune responses can be staggered up, which in turn reduces the severity of the infection. Polysaccharide antigen vaccines stimulate the B-Cell response, which enhances the ingestion and killing of pathogens. The vaccines thereby cut down on the transmissibility and eliminate the need for hospitalization, which have been the major drivers for the Pneumococcal Polysaccharide Vaccine Industry in the projected period of 2022-2027.

Report Coverage

The report: “Pneumococcal Polysaccharide Vaccine Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments of the Pneumococcal Polysaccharide Vaccine Market.

By Vaccine Type- Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine.
By Distribution Channel- Hospitals and Clinics, NGOs, and Government Authorities.
By Geography- North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, and Rest of South America), and Rest of the World (the Middle East, and Africa).

Key Takeaways

• Geographically, North America’s Pneumococcal Polysaccharide Vaccine held a dominant market share in the year 2021. It is owing to the presence of major drug manufacturers and players or their subsidiaries. Additionally, owing to high fatality and disease severity, the population is being regularly taking their vaccine jabs. Moreover, Asia-Pacific is set to offer lucrative growth opportunities to marketers. It is owing to an increasing focus of various governments and NGOs to immunize the people against the following pathogen.

• The increasing awareness pertaining to vaccine usage in avoiding disease fatality and severity has been a key driver for the market. However, owing to supply chain constraints and red-tapisms being followed in the distribution channel have hampered the market growth.

• A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Pneumococcal Polysaccharide Vaccine Market Report.

Pneumococcal Polysaccharide Vaccine Market- Geography (%) for 2021.

For more details on this report - Request for Sample

Pneumococcal Polysaccharide Vaccine Market Segmentation Analysis- By Vaccine Type

The Pneumococcal Polysaccharide Vaccine Market based on vaccine type can be further segmented into Pneumococcal Conjugate Vaccine (PCV) and Pneumococcal Polysaccharide Vaccine (PPV). The PCV market held a dominant market share in the year 2021. It is owing to the wide coverage of the PCV vaccine in various age groups; additionally, multinationals are continually introducing and developing new vaccines with different serotypes. Serotypes are selected based on the prevalence of a particular strain, which is being spread in the region. 

Furthermore, the PCV segment is estimated to be the fastest-growing, with a CAGR of 5.9% over the forecast period of 2022-2027. It is owing to the recent advances, which allows not only the kids but adults in the vaccination program as well. Manufacturers have demonstrated how the said bacteria can lead to mortality in people aged 65+ owing to the various diseases people would have. Additionally, as per US CDC, the geriatric population is expected to take 22% of the entire population segment by 2040, which for now is only 16%. Hence, the segment would observe an increased demand. 

Pneumococcal Polysaccharide Vaccine Market Segmentation Analysis- By Distribution Channel

The Pneumococcal Polysaccharide Vaccine Market based on distribution channel can be further segmented into Hospitals and Clinics, NGOs, and Government Authorities. Non-Governmental Organizations held a dominant market share in the year 2021. It is owing to the various schemes in place and major accords which allow them to hold a significant market share. Furthermore, UNICEF started their PCV vaccine program in 2009, from where they supply close to 1 billion doses of vaccines to 60 or more countries. Moreover, easy access to the vaccine will allow immunizing 300 million children each year.

Moreover, the NGO segment is estimated to be the fastest-growing, with a CAGR of 6.1% over the forecast period of 2022-2027. It is owing to their rising role as being the facilitator to provide vaccines. Further, between 2020-2030, UNICEF plans to immunize more than 1 billion kids each year, which is opening up opportunities to suppliers. Lastly, UNICEF entered into supply agreements with PCV manufacturers for 990,000 doses for humanitarian emergency response activities. To culminate, all the said factors will allow the segment and market to grow.

Pneumococcal Polysaccharide Vaccine Market Segmentation Analysis- By Geography

The Pneumococcal Polysaccharide Vaccine Market based on Geography can be further segmented into North America, South America, Europe, Asia-Pacific, and the Rest of the World. North America held a dominant market share of 34% as compared to others in the year 2021. It is owing to the introduction of vaccines in their adult populations and, moreover, the government’s effort to reduce the caseload and fatality owing to the disease. Lastly, research and development in the following field have helped the region to gain a competitive edge over the others. As per CDC, around 250,000 cases of pneumonia are being hospitalized. Moreover, the death toll is close to 50,000.

However, Asia-Pacific is set to offer lucrative opportunities to marketers owing to the recent development in the field of medical science. Additionally, the giants of India, such as SII or Serum Institute of India, hold a significant place for UNICEF’s promise fulfilments. Owing to such reasons, the regions are estimated to out-grow the other region.

Pneumococcal Polysaccharide Vaccine Market Drivers

The disease severity is reduced by the administration of vaccines has been a key market driver.

Time and again, researchers have advertised those vaccines work. Their working way allows one to suppress the severity of the infection and allows the body to pass it as the flu, thereby, avoiding any cases of hospitalization and fatality. A recent study by Murdoch Children Research Institute established that vaccine receiving children decreases the severity of the disease by 35%. Further, research contributed by a hospital in Laos governed that only one-third of the children who are exposed to pneumonia needs oxygen therapy, however, the risks climb down significantly to the children who have taken the vaccine. As for them, the risk to need supplemental oxygen is close to 20%, as opposed to 33%. Owing to such factors, the vaccines are being regularly deployed.

The awareness pertaining to vaccine usage has allowed the market to grow.

The WHO has created a task force and various other aligned routes with UNICEF to resolve the pneumonia-related deaths. The plan is known as “Global Action for Pneumonia and Diarrhoea. Moreover, the scheme covers three key aspects, which are, PROTECT, PREVENT, and TREAT. In the first dimension, they govern that children should be subjected to take on breastfeeding, while also taking on complementary feeding. Further, in the PREVENT aspect, WHO governs that the children and even the susceptible adults should take the vaccinations pertaining to pneumonia. While in the last aspect, to TREAT, children and afflicted patients should take on the right medications. Additionally, November 12 has now been conferred as World Pneumonia Day, which allows for awareness and stability.

Pneumococcal Polysaccharide Vaccine Market Challenges

The global supply chain has presented itself as a major market challenge.

Vaccines have been termed liquid gold. More so, they are part of illicit activities. For example, there are a lot of barriers and levels between various supply chain levels. Theft, counterfeiting, and sabotage are some of the common activities through which each vaccine passes. Moreover, vaccines that are damaged do not get disposed of, however, the suppliers fill the vials with saline water and end up being marketed in the black market. Secondly, the shortage of professionals who can vaccinate multiples has been a major bottleneck. Further, the buffer capacity field in the market is limited. Any demand exceedingly over 20% cannot be met because of the supply and supply chain constraints. Owing to such factors, the market has been facing constant challenges.

Pneumococcal Polysaccharide Vaccine Industry Outlook

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Pneumococcal Polysaccharide Vaccine Market. The top 10- Pneumococcal Polysaccharide Vaccine Market companies are-

1. GlaxoSmithKline plc.,
2. LG Chem Ltd.,
3. Merck & Co., Inc.,
4. Panacea Biotec Limited,
5. Pfizer Inc.,
6. Pnuvax Incorporated,
7. Serum Institute of India Pvt. Ltd.,
8. Shenzhen Kangtai Biological Products Co., Ltd.
9. SK Bioscience
10. Walvax Biotechnology Co., Ltd.

Recent Developments

• In July 2021, Merck announced that they have received approval for VAXNEUVANCE, which is a Pneumococcal 15-valent Conjugate Vaccine. It will help the adults remain protected against invasive diseases, by providing protection for up to 15 serotypes. Further, the fifteen serotypes are 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in adults. Moreover, the vaccine strictly governs its non-usage for people having a history of anaphylaxis.
• In June 2021, FDA approved Prevnar 20, a vaccine that will help in preventing Pneumococcal disease by providing an accelerated pathway. The disease coverage includes pneumonia, meningitis, and various other infections being caused by Streptococcus pneumoniae. Furthermore, it is approved for all adults over the age of 18 and will help in preventing invasive diseases from up to twenty different types. Some of the side effects include is muscle pain, fatigue, headache, joint pain, and site-swelling.
• In June 2021, Indonesia introduced the PCV vaccine for all people across the country. The country has received 1.6 million doses under the GAVI Commitment. Further, up to 4.5 million children across the nation will be protected, more so, from severe pneumonia. The vaccine coverage will start in a stage vise-manner, and by 2022 it would cover the entire nation. Further, three doses of vaccines will be given to the children at the age of two, three, and twelve months.

Relevant Titles

Vaccines Market- Forecast (2022-2027)
Report Code- HCR 0711

Vaccine Storage and Packaging Market- Forecast (2022-2027)
Report Code- HCR 1383

For more Lifesciences and Healthcare related reports, please click here